Care Dx, Inc. CDNA
We take great care to ensure that the data presented and summarized in this overview for CareDx, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding CDNA
View all-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl5.86MShares$90.9 Million0.44% of portfolio
-
Black Rock Inc. New York, NY5.43MShares$84.1 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.3MShares$66.7 Million0.0% of portfolio
-
State Street Corp Boston, MA4.2MShares$65 Million0.0% of portfolio
-
Bellevue Group Ag Kuesnacht, V83.93MShares$61 Million0.65% of portfolio
-
Sumitomo Mitsui Trust Holdings, Inc.2.75MShares$42.6 Million0.02% of portfolio
-
Nikko Asset Management Americas, Inc.2.75MShares$42.6 Million0.29% of portfolio
-
Gagnon Securities LLC2.25MShares$34.8 Million5.71% of portfolio
-
D. E. Shaw & Co., Inc. New York, NY2.02MShares$31.3 Million0.02% of portfolio
-
Dimensional Fund Advisors LP Austin, TX1.45MShares$22.4 Million0.0% of portfolio
Latest Institutional Activity in CDNA
Top Purchases
Top Sells
About CDNA
CareDx, Inc. discovers, develops, and commercializes diagnostic solutions for transplant patients and caregivers worldwide. It provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company also offers TruSight HLA, a next generation sequencing (NGS) based high resolution typing solution; Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; QTYPE that enables precision in HLA typing; and Ottr, a transplant patient management software. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; and XynQAPI transplant quality tracking and waitlist management solutions, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors and sub-distributors. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies; and Cibiltech SAS to commercialize iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in South San Francisco, California.
Insider Transactions at CDNA
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
May 14
2024
|
George Bickerstaff |
BUY
Exercise of conversion of derivative security
|
Direct |
5,255
+4.77%
|
$52,550
$10.0 P/Share
|
May 01
2024
|
Jeffrey Adam Novack Secretary and General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
1,905
-1.5%
|
$17,145
$9.18 P/Share
|
May 01
2024
|
Abhishek Jain Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
7,371
-2.52%
|
$66,339
$9.18 P/Share
|
May 01
2024
|
Alexander L Johnson Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
7,371
-2.13%
|
$66,339
$9.18 P/Share
|
Apr 29
2024
|
Peter Maag |
BUY
Exercise of conversion of derivative security
|
Direct |
13,281
+3.9%
|
$66,405
$5.27 P/Share
|
Apr 18
2024
|
Abhishek Jain Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
323
-0.11%
|
$2,584
$8.07 P/Share
|
Apr 08
2024
|
Abhishek Jain Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
235
-0.08%
|
$2,115
$9.53 P/Share
|
Apr 04
2024
|
Peter Maag |
BUY
Grant, award, or other acquisition
|
Direct |
1,249
+0.4%
|
-
|
Apr 04
2024
|
Michael Goldberg |
BUY
Grant, award, or other acquisition
|
Direct |
3,686
+2.87%
|
-
|
Feb 05
2024
|
Alexander L Johnson Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,120
-0.65%
|
$8,960
$8.56 P/Share
|
Feb 02
2024
|
Alexander L Johnson Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
4,166
-1.2%
|
$33,328
$8.72 P/Share
|
Feb 01
2024
|
Alexander L Johnson Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
11,245
-6.03%
|
$89,960
$8.88 P/Share
|
Feb 01
2024
|
Abhishek Jain Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
11,469
-8.78%
|
$91,752
$8.88 P/Share
|
Jan 29
2024
|
Alexander L Johnson Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,120
-0.6%
|
$10,080
$9.88 P/Share
|
Jan 12
2024
|
Michael Goldberg |
BUY
Grant, award, or other acquisition
|
Direct |
18,165
+13.05%
|
-
|
Jan 04
2024
|
Michael Goldberg |
BUY
Grant, award, or other acquisition
|
Direct |
3,000
+2.83%
|
-
|
Jan 04
2024
|
Christine Cournoyer Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,288
+5.03%
|
-
|
Jan 04
2024
|
Peter Maag |
BUY
Grant, award, or other acquisition
|
Direct |
1,525
+0.49%
|
-
|
Jan 02
2024
|
Alexander L Johnson Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,047
-0.56%
|
$11,517
$11.94 P/Share
|
Oct 04
2023
|
Christine Cournoyer Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,552
+3.66%
|
-
|
Last 12 Months Summary
Grant, award, or other acquisition | 570K shares |
---|---|
Exercise of conversion of derivative security | 38K shares |
Open market or private sale | 41.6K shares |
---|---|
Payment of exercise price or tax liability | 88.6K shares |